Ace investor Vijay Kedia acquired a significant stake in Mahamaya Lifesciences through a block deal. He purchased nearly 9 lakh shares at Rs 140 each. This transaction highlights investor interest in the agrochemical firm. Mahamaya Lifesciences manufactures pesticide formulations and crop protection products. The company has shown strong financial growth recently. Its shares have performed well since their market debut.
Crude oil shock clouds near-term outlook, but FY27 earnings growth still intact: Karthikraj Lakshmanan
UTI AMC’s Karthikraj Lakshmanan sees cautiously optimistic Indian market outlook with intact FY27 earnings trajectory, despite near-term crude oil volatility. Macro pressures from rising oil
June 1, 2026